Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study.

Background: Mesenchymal chondrosarcoma (MCS) is a distinct, very rare sarcoma with little evidence supporting treatment recommendations.

Patients And Methods: Specialist centres collaborated to report prognostic factors and outcome for 113 patients.

Results: Median age was 30 years (range: 11-80), male/female ratio 1.